This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EYE or NEOG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. NEOG: Which Stock Is the Better Value Option?
ViewRay Allies With Two Majors in MR-Guided Radiation Therapy
by Zacks Equity Research
ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.
RadNet Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
RadNet (RDNT) is optimistic about maintaining momentum on several positive developments.
Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA
by Zacks Equity Research
Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.
BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia
by Zacks Equity Research
BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its stellar performance.
National Vision Holdings, Inc. (EYE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in National Vision Holdings, Inc. (EYE).
Medtronic Displays All-Business-Line Growth Despite Cost Woes
by Zacks Equity Research
Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
Neogen's (NEOG) Food Safety Test Receives AOAC Clearance
by Zacks Equity Research
Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.
Bio-Rad's Blood Typing Market Growth Strong on New Products
by Zacks Equity Research
Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.
Amedisys (AMED) to Broaden Hospice Base With Asana Purchase
by Zacks Equity Research
Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.
Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients
by Zacks Equity Research
Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
NuVasive Gets FDA Nod for CoRoent Small Interlock System
by Zacks Equity Research
NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
EYE vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
National Vision's (EYE) Q3 Earnings Top Estimates, View Raised
by Zacks Equity Research
National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.
National Vision (EYE) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 50.00% and 1.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Reports Next Week: What You Should Expect
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
by Zacks Equity Research
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
National Vision (EYE) Down 11.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.